Dose-escalated radiation does not benefit patients with low-risk prostate cancer

the ONA take:

According to a new study published online ahead of print this week in JAMA Oncology, researchers have found that higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer. However, this association was not observed in patients with low-risk disease.

For the study, researchers analyzed data from 42,481 men with prostate cancer included in the National Cancer Database. Of those, 12,229 had low-risk disease, 16,714 had intermediate-risk disease, and 13,538 had high-risk prostate cancer. Patients were all diagnosed between 2004 and 2006 and received either standard-dose external-beam radiation therapy or dose-escalated radiation.

Results showed that higher dose radiotherapy was associated with increased survival in those with intermediate- and high-risk disease, but not in those with low-risk disease. The findings suggest that aggressive radiotherapy may not be beneficial in men with low-risk prostate cancer, adding to the evidence that watchful waiting or active surveillance may be better for these patients.

Optimizing quality and safety of high dose-rate brachytherapy
Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.
Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs